13 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
. Name and address of MA holder: Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
for pulmonary arterial hypertension.
Kaival Brands Innovations Group, Inc
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
internal and external innovation to best serve patients."
As part of the agreement, Ascentage Pharma
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
.This innovative research collaboration has generated one of the largest cohort data sets globally of HAE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness
yr6gze2ywl1pjokb2321b8jb04mcizmlpjyapabl3b553l gfrt5m
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
rzlny eysrw5jt8r1g
SCLX
TAK
14 May 24
"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
xihsdvme90sytek1l3euic17tgsrgj0 ar0y24ea
ACIU
TAK
13 May 24
in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer's disease
pv8 lblo3wpck5t71gydt0n52dewyl15vfhswgfuywcduyyrdnuv1d
ACIU
TAK
13 May 24
.
"As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change
596frxh9g ukceg
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
sax6uc pnx2ymz0fw0xec
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
v9m7logi 49g0q1hge709c06rxkn50pkl14mxazciesu6p5ev7kbe08
TAK
27 Mar 24
gastrointestinal diseases is unwavering. Alongside our continuous work on innovative treatments within our gastroenterology portfolio, we recognize the significant
aak63y0c1xo6a5y3hfy4cte06l61bgkh tuh1jgfglgnp6c2w
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
- Prev
- 1
- Next